Your browser doesn't support javascript.
loading
Microphysiologically Engineered Vessel-Tumor Model to Investigate Vascular Transport Dynamics of Immune Cells.
Zhao, Yuwen; Wu, Yue; Islam, Khayrul; Paul, Ratul; Zhou, Yuyuan; Qin, Xiaochen; Li, Qiying; Liu, Yaling.
Afiliação
  • Zhao Y; Department of Bioengineering, Lehigh University, Bethlehem, Pennsylvania 18015, United States.
  • Wu Y; Department of Bioengineering, Lehigh University, Bethlehem, Pennsylvania 18015, United States.
  • Islam K; Department of Mechanical Engineering and Mechanics, Lehigh University, Bethlehem, Pennsylvania 18015, United States.
  • Paul R; Department of Mechanical Engineering and Mechanics, Lehigh University, Bethlehem, Pennsylvania 18015, United States.
  • Zhou Y; Department of Bioengineering, Lehigh University, Bethlehem, Pennsylvania 18015, United States.
  • Qin X; Department of Bioengineering, Lehigh University, Bethlehem, Pennsylvania 18015, United States.
  • Li Q; Department of Electrical and Computer Engineering, Lehigh University, Bethlehem, Pennsylvania 18015, United States.
  • Liu Y; Department of Bioengineering, Lehigh University, Bethlehem, Pennsylvania 18015, United States.
Article em En | MEDLINE | ID: mdl-38652824
ABSTRACT
Cancer immunotherapy has emerged as a promising therapeutic strategy to combat cancer effectively. However, it is hard to observe and quantify how this in vivo process happens. Three-dimensional (3D) microfluidic vessel-tumor models offer valuable capability to study how immune cells transport during cancer progression. We presented an advanced 3D vessel-supported tumor model consisting of the endothelial lumen and vessel network for the study of T cells' transportation. The process of T cell transport through the vessel network and interaction with tumor spheroids was represented and monitored in vitro. Specifically, we demonstrate that the endothelial glycocalyx serving in the T cells' transport can influence the endothelium-immune interaction. Furthermore, after vascular transport, how programmed cell death protein 1 (PD-1) immune checkpoint inhibition influences the delivered activated-T cells on tumor killing was evaluated. Our in vitro vessel-tumor model provides a microphysiologically engineered platform to represent T cell vascular transportation during tumor immunotherapy. The reported innovative vessel-tumor platform is believed to have the potential to explore the tumor-induced immune response mechanism and preclinically evaluate immunotherapy's effectiveness.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article